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Abstract
Background: Rituximab, a monoclonal antibody directed against CD20, is approved for the treatment of
CD20-positive B-cell Non-Hodgkin’s lymphoma and rheumatologic disorders. Due to its potent activity in depleting
CD20-positive lymphocytes, the influence on opportunistic infections is still under discussion. Thus, we analyzed the
impact of rituximab either as monotherapy or in combination with other chemotherapeutic regimens to elucidate its
role in contributing to infectious complications.
Methods: The records of consecutive patients (n = 125, 141 treatment episodes) treated with rituximab alone
or in combination with chemotherapy and corticosteroids were analyzed retrospectively for the incidence,
spectrum and outcome of infections during treatment and 6 months after the last course of rituximab.
Univariate analysis of cofactors such as steroid medication, antiinfective prophylaxis, underlying disease and
remission status were performed.
Results: Altogether 80 therapy episodes were associated with infections, the median number of infections per
patient being 1 (range 1–7). The number of infectious complications was significantly higher in patients
receiving a combination of rituximab and chemotherapy compared to rituximab monotherapy (p < 0.001). There
was no statistically significant difference regarding number of rituximab courses or cumulative rituximab dosage
between episodes with and without infections, respectively.Mean cumulative prednisone dosage between the
cohort with infections and the one without infections showed a trend towards higher dosage of prednisone in
the patients with infections (mean difference 441 mg, p > 0.14).
Conclusions: Rituximab in induction treatment, either as monotherapy or combined with chemotherapy by
itself does not increase the incidence or change the spectrum of infections in hematologic patients. However
the possible influence of higher dosages of concomitant steroid medication on frequency of infections suggests
that a heightened awareness of the potential for infectious complications should be applied to patients
receiving higher doses of glucocorticoids in combination with other therapeutic regimens.
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Background
Rituximab, a monoclonal antibody directed against the
CD20 epitope, was approved in 1998 in Europe for treat-
ment of CD20-positive B-cell non Hodgkin’s lymphoma.
It has shown significant increase of survival in B-cell
malignancies and has become standard of care in various
entities of lymphomas and other malignant hematologic
diseases. Recent data furthermore suggests an even better
outcome for indolent B-cell malignancies if rituximab is
continued after the end of the chemotherapeutic regimen
as a maintenance treatment [1] for follicular lymphoma
and for mantle cell lymphoma [2]. Due to its good activity
in a variety of autoimmune diseases rituximab has been
approved for the treatment of rheumatoid arthritis
(RA) [3] and ANCA-associated vasculitis [4]. Beyond
its approval, rituximab is being used and/or evaluated for
further disease entities like immune thrombocytopenia [5],
autoimmune hemolytic disease [6], posttransplant lym-
phoproliferative disorders [7] and multiple sclerosis [8].
Based on these data, the principle of anti-CD20-based
monoclonal therapy has lead to research in more agents
targeting CD20, namely Ofatumumab (Arzerra®), approved
for chronic lymphocytic leukemia and more recently
Obinutuzumab [9].
As CD20 is also expressed on healthy cells, there are
concerns that the incidence of infections may increase:
Treatment with rituximab leads to a pronounced deple-
tion of pre-B-cells and mature-B-cells for several months,
with levels returning to normal about 12 months after the
last application. As CD20 is not expressed on healthy
plasma cells, immunoglobulin levels were initially thought
to be unaffected by rituximab treatment [10], recent data
however, suggest an increased risk of hypogammaglobuli-
nemia for patients during maintenance treatment [11].
Moreover, late-onset neutropenia after rituximab adminis-
tration has been described repeatedly [12].The risk of
infectious complications in patients receiving rituximab is
still under discussion: Although some groups found an
increase in infections [13] for NHL patients, others could
not reproduce that finding [14] for NHL. A recent met-
analysis covering three randomized controlled trials also
failed to find an increase in infections in RA patients
treated with rituximab [15]. However, judging the influ-
ence of rituximab on incidence of infection is difficult as
this agent is often part of a complex treatment regimen
consisting of different chemotherapeutic drugs with each
having a specific immunosuppressive effect. Indeed, in a
randomized, phase III study evaluating the effect of rituxi-
mab maintenance treatment, the rate of CTC grade 3 or 4
neutropenia and rate of infectious episodes were signifi-
cantly increased [1]. In renal transplant patients treated
with rituximab, Kamar et al. described that the addition of
rituximab to anti-thymocyte-globulin was an independent
predictive factor for infection-related death [16] and a
recent study showed that allogeneic stem cell recipients
treated with rituximab for reactivation of Ebstein-Bar-
Virus (EBV) had a moderate, but statistically significant
higher non-relapse mortality due to an increase in bacter-
ial infections [17].
A recent finding that has been acknowledged and which
lead to a black-box-warning of the FDA is the statistical
increase in progressive multifocal leucencephalopathy
(PML) caused by reactivation of the JC virus initially
observed in NHL patients but also recognized in RA
patients treated with rituximab. A retrospective analysis
recently described a significant higher incidence of PML
cases for rituximab-treated patients [18], although it has
to be kept in mind that NHL patients by itself do carry an
increased incidence of PML.
Taken together, the exact influence of rituximab on in-
cidence of infections is still controversial, probably de-
pending on concomitant immunosuppressive medication
(e.g. chemotherapy) and underlying disease. However,
studies focusing on infectious complications of rituxi-
mab therapy are rare. In order to elucidate on that topic
we performed a monocentric retrospective analysis by
analyzing consecutive hematologic patients treated with
rituximab in the timeframe from 2000 – 2005 for a var-
iety of diseases for incidence and spectrum of infections
as well as other factors contributing to infections,
thereby trying to elucidate the role of rituximab in con-
tributing to infection.
Methods
The study was performed retrospectively on a cohort of
unselected consecutive pts treated in the Hematology
Department of the University Hospital of Mannheim with
rituximab +/− chemotherapy between the 1st of February
2000 and the 31st of January 2005. The patients’ records
were analyzed for the incidence of fever +/− infections
and other clinical factors during treatment and 6 months
after the last course of rituximab. Written informed con-
sent for data collection was obtained within the consent
procedure for cancer treatment and specialized medical
care. As the study was done to retrospectively investigate
clinical data of patients treated solely at our institution in
a scientific intent and data were obtained anonymized
concurrently, an approval of the local ethics committee
(Ethics Committee, Faculty of Medicine Mannheim) was
not required according to the German Ethics Committees
regulations [19]. The study was performed in compliance
with the Declaration of Helsinki.
Patient characteristics
The study was performed on a cohort of 125 pts (male:
69, female: 56) of a median age of 65 years (range 16–87
years) and 141 therapy episodes were analyzed. Underlying
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diseases, chemotherapeutic regimens and comorbidities
are depicted in Table 1.
Documented items
Patients’ records were analyzed for white blood cell
count (WBC) and differential WBC counts, grading of
WBC was done according to common-toxicity criteria 4.0
(CTC, http://evs.nci.nih.gov/ftp1/CTCAE/About.html)
of the national cancer institute (NCI). T-cell deficiency
was defined as CD4 + −cell percentage <25% or <450/μL,
CD8 + −percentage <19% or <250/μl. Hypogammaglobuli-
nemia was defined as aɣ-Globulin <8.7%, immunoglobulin
deficiency was defined as serum IgG < 7,0 g/L, serum
IgA <0.7 g/L or serum IgM < 0.4 g/L. The underlying
disease as well as its stage and remission status were
documented. Relapse was defined as a reoccurrence of
symptoms or manifestations after obtaining complete
remission for > =2 months, progressive disease was de-
fined as a reoccurrence of symptoms or manifestations
after obtaining at least a partial remission. All prior
therapies as well as cumulative rituximab doses and dos-
age were documented and analysed. Type, dosage and
duration of concomitant medication with known influence
on infections (e.g. steroid dosage expressed in prednisone-
equivalent) were analyzed and calculated. Comorbidities
known to influence the risk of infection (e.g. diabetes mel-
litus, chronic obstructive pulmonary disease (COPD))
were included into the analysis. Supportive therapeutic
measures like application of Granulocyte-colony–stimu-
lating factor (G-CSF) and antiinfectious prophylaxis
with Trimethoprim/Sulfamethoxazole (TMP-SMX) were
documented.
Table 1 Characteristics of patients
Characteristics (n = 141) Maximum CTC grade 1&2 infection Maximum CTC grade 3&4 infection
Underlying disease
Indolent NHL 80 4 33
CLL 4 1 0
Aggressive NHL 49 6 32
ALL 4 0 3
AIHA 3 0 1
ITP 1 0 0
Therapeutic regimens used (n = 141)
Rituximab monotherapy 23 1 3
R-CHOP 84 7 42
R-CHOEP 4 1 3
R-FC 6 2 4
R-FCM 2 0 0
R-DHAP 2 0 2
R-GMALL 7 0 5
R-Bendamustin 4 0 1
R-IMVP16 2 0 2
R-Gemcitabin 1 0 1
R-other 6 0 6
Comorbidities
Diabetes mellitus 18
Immunoglobulin deficiency 10
Asplenia 7
COPD 5
Chronic sinusitis 3
CTC: common toxicity criteria 4.0 of the National Institute of Health; NHL: non-Hodgkin lymphoma; CLL: chronic lymphocytic leukemia; ALL: acute lymphoblastic
leukemia; AIHA: autoimmune hemolytic anemia; ITP: immunothrombocytopenic purpura, R-CHOP: Rituximab, cyclophosphamide, adriamycin, vincristine, prednisone;
R-CHOEP: Rituximab, cyclophosphamide, adriamycin, vincristine, etoposide, prednisone; R-FC: Rituximab, fludarabine, cyclopsphamide; R-FCM: Rituximab, fludarabine,
cyclopsphamide, mitoxantrone; R-DHAP: Rituximab, cytarabine, cisplatin, dexamethasone; R-GMALL: Rituximab in combination with the german GMALL induction; protocol
for ALL-therapy; R-Bendamustin: rituximab and bendamustine; R-IMVP16: Rituximab, ifosfamide, etoposide, methotrexate; R-other: consisting of combination of other
therapies such as R-DAHP +DB, R-CHOEP + R-BALL/BNHL, R-FCM + R-Bendamustin, R-FC + R-liposomal Doxorubicin, R-FCM+ R-HAP, R-CHOP+ R-FC + R-Bendamustine,
COPD: chronic obstructive pulmonary disease.
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Events judged as infectious episodes had to either
provide a microbiologically documented infection (e.g.
positive cultures), radiomorphologic signs of infections
(e.g. pulmonary infiltrates) or fever of unknown origin
(FUO). FUO was defined as a febrile episode ≥ 38.5°C
where no infectious agent or focus had been obtained
in the routine screening program consisting of a minimum
of microbiological cultures, chest x-ray and abdominal
ultrasound and other reasons (e.g. drug-induced fever)
could be clinically ruled out. Diarrhea was defined as be-
ing of infectious nature if no other cause could be identi-
fied (e.g. toxic, concomitant medication). Opportunistic
infections were defined as viral or fungal infections caused
by known opportunistic pathogens. All infections were
graded according to the CTC of the NCI.
Statistical analysis
Patients’ data was collected, anonymized and inserted in
a database (Microsoft Excel 2010; Microsoft Software,
Redmond, USA). Descriptive statistics were performed
using SAS software release 8.2 (SAS Institute, Cary, USA).
Statistical tests consisted of the student t-test as well as
the chi-square test. P values of less than .05 were consid-
ered statistically significant. Where applicable, relative risk
of infection was determined by calculating the odds ratio.
For multivariable analyses, a linear regression ana-
lysis was performed. All variable, who were found to
yield p-values of less than 0.1 in univariable analysis
entered the multivariable model: The multivariable
analyses were carried out with the SAS soft-ware, release
8.2 (SAS Institute, Cary, NC, USA).
For all statistical analyses patients who developed one
or more infections were compared to the patients who
did not develop an infection in the observed time period
and who acted as the control group.
Results
In total, 141 treatment phases (=cases) of 125 patients
were evaluated. During the treatment phase and follow
up, altogether 80 therapies were associated with infections,
the median number of infections per patient being 1 (range
1–7). 61 therapeutic phases were not associated with an
infectious episode in the observed time period.
The total number of infections registered was 138, in
45 and 35 treatment courses one and more than one
infection (range 2–7) was found, respectively. Altogether
23 opportunistic infections were recognized, in one case,
two opportunistic infections were noted. Forty-nine epi-
sodes of infection developed during hospitalization, in 58
infectious episodes, hospitalization was clinically indicated
and 31 infectious episodes could be treated in an out-
patient setting. In 88/138 infectious episodes intravenous
antimicrobials were applied, in 46 episodes oral or local
treatment was sufficient. Grading of infections according
to CTC criteria revealed infections to be typically severe
with 11 episodes consisting of grade 4 infections, 104 epi-
sodes being grade 3 infections and only a few mild infec-
tions (grade 2 = 23; grade 1 = 0). There was no difference
of incidence of infection with regards to age, gender or
grading of infections.
During the observation period, altogether 17 patients
died. The majority (n = 14) of patients died either due to
progressive disease or complications while suffering from
progression of the underlying malignancy. Three of these
patients died from pneumonia while having progressive
disease and one patient while being in remission died to a
disseminated Varicella zoster virus (VZV) infection.
Microbiological spectrum of infectious episodes
In 59% of all infectious episodes no causative infectious
agent could be identified. In the rest of these episodes the
majority of observed pathogens were of bacterial origin
(23%), with virus (14%) and fungi (4%) being the minority
of observed infectious pathogens. Table 2 depicts the mi-
crobial spectrum and the site of detection of the infectious
organism.
Time of infection
Median time of infection was 99 days after first adminis-
tration of rituximab (range 1 – 566 days) (Figure 1). Rate
of infections decreased with increasing distance to last
application of therapy.
Relationship of incidence of infection to other
assessed factors
The combination of chemotherapy with rituximab lead to
infections in 76/118 cases (64%), while rituximab mono-
therapy lead to infectious complications in only 4/23 cases
(n = 17%). The number of infectious complications was
significantly higher in patients receiving a combination
of rituximab and chemotherapy compared to rituximab
monotherapy (p < 0.001).
Influence of chemotherapeutic regimen on incidence
of infection
For patients receiving R-CHOP or R-CHOEP regimen,
we identified 27 cases of infection (51%) for patients
receiving R-CHOP/R-CHOEP therapy every 21 days
(R-CHOP-21, R-CHOEP-21). For patients with intensified
treatment consisting of R-CHOP or R-CHOEP every
14 days (R-CHOP-14 or R-CHOEP-14), the rate of infec-
tious episodes was 26/35 episodes (74%). There was a sig-
nificant increase of the rate of infection for patients
receiving time-intensified R-CHOP/R-CHOEP every 14 days
compared to the 21-days regimen (p < 0.03). Table 3 depicts
the chemotherapeutic regimen and the identified focus of
the infectious organism.
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Influence of rituximab dosage or number of doses on
incidence or spectrum of infections
All patients were analyzed for the number of doses of
rituximab and cumulative rituximab dosage. Rituximab
standard dosage per course consisted of 375 mg/sqm, no
dose escalation had been performed. Treatment courses
associated with infections were compared with those with-
out an infection during the observation period. Of the 80
treatment doses with infections, the number of adminis-
tered rituximab doses was 6 and cumulative dosage was
3600 mg, whereas it was 5 doses and a cumulative dosage
of 3500 mg for the patients without infections. There was
no statistically significant difference in either number of
doses or cumulative rituximab dosage when comparing
courses with infectious complications (n = 80) compared
to those without infections (n = 61) (p > 0.77).
Influence of concomitant steroid medication on incidence
or spectrum of infections
Median cumulative prednisone-dosage of all patients
with infectious complications was 3500 mg prednisone
while median cumulative prednisone-dosage of all those
without infection was only1800 mg. When comparing
cases with infectious complications (n = 80) compared to
those without infections (n = 61) we found a significant
higher amount of prednisone as concomitant medication
for those with infections (p < 0.0003).
However, when performing a subgroup analysis of only
those cases with rituximab in combination with chemo-
therapy (n = 118) (thus leaving out patients with rituximab
monotherapy to avoid a potential bias), this significance
was lost, although a trend towards higher mean cumu-
lative prednisolone dosage in patients with rituximab-
chemotherapy and infectious complications could still
be observed (3220 mg vs 2778 mg, p > 0.14).
Influence of WBC/differential blood cell count disease on
incidence or spectrum of infection
Seventy-four cases who developed neutropenia during
antineoplastic therapy were identified. Of those, 55/74
(74%) developed an infectious episode, one patient devel-
oped neutropenia while receiving rituximab monotherapy.
Contrarily, treatment cases who did not develop neutro-
penia only suffered from an infectious complication in
37% (25/67).
Patients with infections suffered significantly more often
from neutropenia compared to those without infections
(p < 0.001).
Age and comorbidity
When comparing cases with infectious complications
(n = 80) compared to those without infections (n = 61)
no statistical significant difference was identified for age
(p > 0.69). When assessing the influence of comorbidities
known to predispose for infections we found no signifi-
cant difference for the following comorbidities: Diabetes,
immunoglobulin deficiency, asplenia, chronic obstructive
pulmonary disease and chronic sinusitis (p > 0.63).
Supportive therapy and antiinfective prophylaxis
Altogether 63 cases received G-CSF after chemo-im-
munotherapy in the corresponding treatment phases; of
Table 2 Types of infection and infectious pathogen
observed
Type/localization of infection n Infections CTC
grade 1&2
Infections CTC
grade 3&4
FUO 37 0 37
Upper respiratory tract infections 14 3 11
Urinary tract infections 16 10 6
Pneumonia 18 0 18
Bronchitis 10 6 4
Herpes zoster 10 3 7
Herpes labialis 5 3 2
Sepsis/bacteremia 10 0 10
GI-tract infections 6 2 4
Mucocutaneus candidiasis 2 1 1
Erysipel 2 0 2
Sinusitis 2 0 2
Cerebral aspergillosis 1 0 1
Other 4 2 2
Infectious agent
Viral infections 19
Varicella Zoster 10 3 7
Herpes simplex 6 3 3
Cytomegaly 1 0 1
Norovirus 2 1 1
Fungal infections 6
Aspergillus spp. 2 0 2
Candida spp. 4 1 3
Bacterial infections 32
Escherichia coli 6 4 2
Campylobacter 1 0 1
Enterobacter 1 0 1
Salmonella 1 0 1
Staphylococcus epidermidis 10 2 8
Enterococcus spp. 2 0 2
Clostridium difficile 1 1 0
Combined# 10 4 6
FUO: Fever of unknow norigin; other: Conjunctivitis, orbital phlegmonia,
spondylodiscitis; # = combined infections: Klebsiella pneumonia, Proteus
mirabilis, Pseudomonas aeruginosa; Strepococcus salivarius, Streptococcus mitis
oralis, Corynebacteria spp., Staphylococcus aureus.
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those, 20 did not develop an infectious episode while the
remaining 43 cases were associated with an infectious
complication. Of cases developing infections (n = 80), 43
(54%) had been administered G-CSF in a prophylactic
intention, whereas, only 20 cases (33%) of the patients
without infections had received G-CSF.
Of those cases receiving TMP-SMX (n = 52), 42 (80%)
developed an infectious complication, while 10 (19%)
remained without infectious complications. Intravenous
immunoglobulins were administered in 7/141 cases due
to known hypogammaglobulinemia, 4 of these developed
an infection.
Statistical influential variables
When comparing the cases in which an infection developed
(n = 80) with those without infections (n = 61) nominally
scaled variables were analyzed and listed in Table 4.
For the ordinally scaled variables assessed using the
means and comparing the group with infections compared
to those without infectious complications in this analysis
the following results were found using a two-sided t-test:
There was no statistically significant difference regard-
ing number of rituximab courses, cumulative rituximab
dosage or patients’ age in the two groups with and without
infections, respectively.
Discussion
To investigate the incidence and spectrum of infections
during and after rituximab treatment and evaluate other
confounding variables which might contribute to the
development of infectious complications, we performed
this monocentric study.
For the interpretation of our study, it has to be kept in
mind that it was done prior to wide-spread use of rituxi-
mab maintenance therapy which maximizes the amount
of rituximab exposure and which makes evaluating the
immunosuppressive effect of rituximab itself much easier
as the confounding effect of the coadministered chemo-
therapeutic regimen is not present. As rituximab is an in-
tegral part of treatment regimens in certain hematologic
disease groups, a direct comparison between treatment
groups with and without rituximab is not possible. We
therefore could only compare the incidence of infections
during rituximab to historic controls without rituximab.
Additionally, we analyzed all patients treated with rituxi-
mab and compared those with infectious complications to
the ones without, trying to analyze in depth which factors
contribute to these complications.
The overall incidence of infections in our study popu-
lation is comparable to corresponding patient groups
who received similar chemotherapy without rituximab.
In the main patient group, i.e. patients receiving R-CHOP
or R-CHOEP, the infection rate was higher in the group
with a 14 day treatment interval as compared to the group
with the 21 day interval. This is in accordance with other
studies [20-22].
The spectrum of infections and pathogens is compar-
able to those reported in other studies, apart from one
patient who had proven cerebral aspergillosis during
R-CHOP treatment for NHL. Invasive fungal disease
Figure 1 Infection relative to start of treatment 1 with Rituximab.
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Table 3 Regimen, spectrum and type of infection
Cases with
infections
Number of
infectious episodes
Focus of
infection
Opportunistic
infections
Identified
pathogen
Number of CTC
grade 3+4 infections*
Rituximab monotherapy (n = 23) 4 4 Pneumonia (n = 1) 2 none (n = 2) 3
viral (n = 2)Opp. Inf. (n = 2)
Bronchitis (n = 1)
R-CHOP/R-CHOEP (n = 88) 53 80 UTI (n = 12) 15 none (n = 47) 66
bacterial (n = 17)URTI (n = 11)
Opp. inf. (n = 12) viral (n = 15)
Opp. Pneumonia (n =5) fungal (n = 3)
Bronchitis (n = 5)
FUO (n = 22)
Sepsis (n = 2)
R-FC/R-FCM (n = 8) 6 9 Bronchitis (n = 3) 2 none (n = 4) 4
bacterial (n = 3)OppInf (n = 2)
viral (n = 2)UTI (n = 1)
FUO (n = 2)
Sepsis (n = 1)
R-GMALL/R-DHAP (n = 9) 7 19 UTI (n = 2) 2 none (n = 12) 16
bacterial (n = 5)Pneumonia (n = 2)
fungal (n = 2)FUO (n = 8)
Sepsis (n = 4)
URTI (n = 1)
Opp Pneumonia (n = 1)
Sinusitis (n = 1)
R-Gemcitabine (n = 1) 1 1 Pneumonia (n = 1) none 0 1
R-IMVP16 (n = 2) 2 3 FUO (n = 1) 1 none (n = 2) 3
viral (n = 1)URTI (n = 1)
OppInf (n = 1)
R-Bendamustine (n = 4) 1 3 Pneumonia (n = 1) None none (n = 1) 3
Sepsis (n = 1) bacterial (n = 2)
UTI (n = 1)
R-Other (n = 6) 6 19 FUO (n = 4) 1 none (n = 13) 19
Norovirus (n = 1) viral (n = 1)
Diarrhea (n = 3) bacterial (n = 4)
Pneumonia (n = 4) fungal (n = 1)
Sepsis (n = 3)
Bronchitis (n = 1)
URTI (n = 1)
Sinusitis (n = 1)
Opp. Inf. (n =1)
UTI = urinary tract infection, URTI = upper respiratory tract infection, FUO = fever of unknown origin, Opp = Opportunistic.
*in 35 cases more than one infection occured.
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has so far been only reported with rituximab in combin-
ation with more intensive chemotherapy or after trans-
plantation [23]. Whether rituximab increases the risk for
invasive fungal disease cannot be stated from our data and
will have to be investigated in larger patient numbers.
Similar as was recently presented by Lanini et al. [14]
we could not detect a difference in rituximab dosage
between those presenting with infection and the ones
without, which is in line with the report mentioned
above, suggesting, that, at least when combined with
chemotherapy the influence of rituximab as an additional
factor for infections is negligible. However, that data has
to be interpreted with care, as the follow-up of our study
was 6 months after end of therapy. Indeed in one of the
major studies comparing the R-CHOP with the CHOP
regimen for treatment of aggressive NHL [24] a trend for
late infections was observed for the rituximab-containing
regimen and could be at least partially attributed to in-
creasingly recognized late-onset neutropenia induced
by rituximab [25]. Another study for chronic lymphocytic
leukemia patients evaluated the effect of ritxuximab when
added to a regimen consisting of fludarabine and cyclo-
phosphamide (FC); despite a longer follow up of 12 months,
they could not find an increase in infections [26].
Recent data analyzing maintenance therapy however,
show a significant increase in grade 3 and 4 infections
for lymphoma patients receiving rituximab maintenance
[1] compared to patients under observation, underlining
that there is a potential for infections complications
when receiving constant, steady dosages of rituximab,
which prevents a regeneration of B-cell levels: The mean
cumulative dosage of rituximab in our study was 3760 mg,
which is much lower than the cumulative dosage of pa-
tients receiving induction and maintenance therapy with
rituximab: In the study presented by Van Oers’, patients
received 14 doses of rituximab treatment which accounts
for at least 5250 mg/sqm per patient and which is nearly
thrice the cumulative rituximab dosage of the patients
studied in our trial, which might explain the different
effects on infection incidence. Furthermore, the immuno-
suppressive effect of rituximab might be negligible com-
pared to the pronounced effect of neutropenia-inducing
chemotherapeutic regimens, but might become more ap-
parent when compared with observation in maintenance
therapy.
Taken together, our data suggest that the addition of
rituximab does not increase the risk of infectious compli-
cations substantially at least during combined chemo-
immunotherapy though its effect in maintenance therapy
cannot be determined as our study only contained 6 pa-
tients during maintenance therapy. Though rituximab did
not have an effect regarding the incidence of infections in
Table 4 Statistical influential variables
Variable P-value (infections vs. No infection) Odds ratio (95%CI)
Gender 0,43 0,76 (0.39-1.49)
Age (≤60,<60 years) 0,69 1.15 (0.57-2.35)
Stage 0,076 n.a
Number of prior therapies 0,015* n.a.
Number of doses of Rituximab 0,35 n.a.
Chemotherapy in addition to Rituximab 0,006* n.a.
Asplenia 0,45 0.56 (0.12-2.58)
Active malignancy at start of therapy§ 0,007* 6.75 (1.4-32.5)*
Active malignancy at end of therapy 0,02* 3.06 (1.14-8.17)*
Application of G-CSF 0,013*# 2.38 (1.19-4.76)
Cotrimoxazole prophylaxis 0,0001*# 5.64 (2.51-12.64)
HIB/pneumococci vaccination 0,09 0.18 (0.02-1.66)
Substitution of immunoglobulins 0,45 0.56 (0.12-2.58)
Neutropenia 0,0001* 4.86 (2.37-9.99)*
Lymphopenia 0,045* 6.96 (0.79-61.26)*
Leukopenia 0,0001* 4.51 (2.09-9.74)*
Relevant comorbidities 0,63 1.16 (0.54-2.49)
*statistically significant in univariate analysis.
n.a.: not applicable.
§ as patients with maintenance therapy and nonmalignant disorders had been treated with Rituximab not all patients had active malignancy at start of therapy.
#Paradoxically, patients with infectious complications had significantly more often been treated with G-CSF and received Cotrimoxazole prophylaxis, probably as
these antiinfective measures had been administered to patients receiving more intensive chemotherapeutic regimens (such as GMALL, or R-CHOEP).
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our patient cohort, we possibly identified the cumulative
steroid dosage to have a potential influence on the in-
cidence of infections.
Evaluating the effect of steroids on infectious complica-
tions in chemotherapy patients is difficult as the majority
of chemotherapeutic regimens contain glucocorticoids
(e.g. CHOP, DHAP, Dexa-BEAM, etc.) and at least to
our knowledge no randomized trial directly comparing a
steroid-containing regimen to glucocorticoid-free regimen
are published. For other hematologic diseases, data from
myeloma trials elucidate the pronounced influence of
high-dosed glucocorticoid medication on infectious com-
plications: A recent monocentre experience suggests for
patients receiving a combination of vincristine and adria-
mycin +/− intermittent high-dose dexamethasone that
there is a significant decrease in rate of infections when
abstaining from use of concomitant steroids [27]. In a
multicenter trial evaluating the effect of high-dose dexa-
methasone versus low-dose dexamethasone in combin-
ation with lenalidomide for first-line myeloma treatment
there was a significant increase in infectious complications
for patients in the high-dose steroid group, underlining
the influence of steroid dosage when added to another
potentially immunosuppressive therapeutic regimen [28].
Especially for opportunistic infectious pathogens like As-
pergillus spp., high dose steroids are a major independent
factor for invasive aspergillosis and also confer an inferior
prognosis in hematologic patients after allogeneic trans-
plantation [29]. Furthermore, they are an independent risk
factor for IA even for otherwise non-immunocompromised
patients [30]: In a recent analysis [31] the majority
of hematologic patients treated with rituximab with
Pneumocystis jirovecii pneumonia had high-dose gluco-
corticoid exposure, underlining the pronounced effect of
steroid co-medication in the pathogenesis of opportunistic
infections.
Patients having infections in our study had a trend
towards higher cumulative steroid dosages, however this
effect was clearly less pronounced and lost its statistical
significance when leaving out patients receiving rituximab
monotherapy, possibly due to the lower amount of pred-
nisolone in that less intensive, regimen.
A result in our study, which might seem contradictory
at first, was that administration of G-CSF or TMP-SMX
prophylaxis was present more frequently in the cohort
with infectious complications. A possible explanation is
that, as this was a retrospective, real-life observation,
prophylaxis was not mandatory in patients; only 37% of all
patients received TMP-SMX prophylaxis and 45% were ad-
ministered G-CSF. This seemingly paradoxical result can
be explained by the fact that patients with either a more
intensive chemotherapeutic regimen (e.g. R-CHOP-14,
R-DHAP, R-GMALL) or a regimen known for having
more infectious complications (R-FC, R-FCM) received
TMP-SMX prophylaxis and/or G-CSF, whereas those with
less intensive regimens (e.g. R-CHOP21) did not. Indeed,
though only a minor number of patients received R-FC or
R-FCM and all were administered prophylaxis, we could
detect a higher incidence of all infections in R-FC/R-FCM
compared to patients with R-CHOP/R-CHOEP despite
these prophylactic measures, however CTC grade 3/4 and
thus severe infections were similar between R-FC/R-FCM
and R-CHOP/R-CHOEP.
Our study has several limitations that need to be ad-
dressed: First, due to the retrospective, “real-life” design
of our study, as we sought to identify factors discriminating
patients with infectious complications from those without,
we did not perform pair-matched analyses. Therefore it
cannot be ruled out that there are other confounding fac-
tors which discriminate the groups and possibly influen-
cing the results. Second, the late infections increasingly
reported might have been missed as the follow-up was
only 6 months. Third, as the trial ended in 2005, only a
small minority of patients (n = 6) were already receiving ri-
tuximab maintenance treatment so the effect of rituximab
maintenance treatment on incidence or spectrum of infec-
tions cannot be assessed from our data. Finally, another
drawback of our study is that the study population is ra-
ther heterogeneous, regarding the underlying disease and
the applied chemotherapy regimen. Preferably, a more
homogeneous study population should be assessed.
Conclusions
In summary, our data suggests that rituximab in induc-
tion treatment, either as monotherapy or combined with
chemotherapy, by itself does not increase the incidence or
change the spectrum of infections in hematologic patients.
However a potential influence of higher dosages of con-
comitant steroid medication on frequency of infections
may be present suggesting that a heightened awareness of
the potential for infectious complications should be ap-
plied to patients receiving higher doses of glucocorticoids
in combination with other therapeutic regimens.
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